Insulinoma screening: Difference between revisions

	Insulinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Insulinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
X-ray
Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Insulinoma screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Insulinoma screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Insulinoma screening
CDC on Insulinoma screening
Insulinoma screening in the news
Blogs on Insulinoma screening
Directions to Hospitals Treating Insulinoma
Risk calculators and risk factors for Insulinoma screening

Revision as of 19:46, 15 August 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]

There is insufficient evidence to recommend routine screening for insulinoma

@@ Line 1: / Line 1: @@
 __NOTOC__
 {{Insulinoma}}
-{{CMG}}; {{AE}} {{PSD}}
+{{CMG}}; {{AE}} {{ADS}}
 ==Overview==
-There is insufficient evidence to recommend routine screening for [disease/malignancy].
+There is insufficient evidence to recommend routine screening for insulinoma
-OR
-According to the [guideline name], screening for [disease name] is not recommended.
-OR
-According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
 ==Screening==